Role for protease activity in visceral pain in irritable bowel syndrome
J. Clin. Invest. Nicolas Cenac, et al. 117:636
doi:10.1172/JCI29255 [Go to this article.]

Figure 6
Visceral sensitivity in response to human colonic biopsy supernatants. Recordings of mouse abdominal muscle contraction in response to colorectal distension before (control) or 6 hours after intracolonic administration of ascending colon biopsy supernatants from IBS patients (A and B) or control patients (filled triangles in C). (A) Representative traces of mouse abdominal muscle contractions in response to 60 mmHg colorectal distension, in PAR2+/+ or PAR2–/– mice before (control) or after intracolonic (i.c.) administration of IBS ascending colon biopsy supernatant alone or in combination with the protease inhibitor FUT or a PAR2 antagonist. (B) Abdominal contraction responses to different pressures of distension (15–60 mmHg) before (time 0) or after intracolonic administration of IBS patient ascending colon biopsy supernatants. Data are mean ± SEM; n = 8. *P < 0.05, **P < 0.01, ***P < 0.005 compared with basal (time 0) measurements. (C) Mouse abdominal contraction response to increasing pressures of distension in PAR2+/+ or PAR2–/– mice before (control distension) or 6 hours after intracolonic administration of IBS biopsy supernatants (filled squares) alone or in combination with the protease inhibitor FUT or a PAR2 antagonist or after the intracolonic administration of biopsy supernatants from control patients (filled triangles). Data are mean ± SEM; n = 12 for the biopsy supernatants from control patients; n = 18 for IBS biopsy supernatants. *P < 0.05, **P < 0.01, ***P < 0.005 compared with control distension. For all data in this figure, biopsies were collected from the ascending colon.